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Oncogenic AKTivation of translation as a therapeutic target
AC Hsieh1,2, ML Truitt1 and D Ruggero*,1
1Department of Urology, School of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, Helen Diller
Family Cancer Research Building, Room 386, 1450 3rd Street, San Francisco, CA 94158-3110, USA; 2Division of Hematology/Oncology, University
of California, San Francisco, Helen Diller Family Cancer Research Building, Room 386, 1450 3rd Street, San Francisco, CA 94158-3110, USA
The AKT signalling pathway is a major regulator of protein synthesis that impinges on multiple cellular processes frequently altered in
cancer, such as proliferation, cell growth, survival, and angiogenesis. AKT controls protein synthesis by regulating the multistep process
of mRNA translation at every stage from ribosome biogenesis to translation initiation and elongation. Recent studies have highlighted
the ability of oncogenic AKT to drive cellular transformation by altering gene expression at the translational level. Oncogenic AKT
signalling leads to both global changes in protein synthesis as well as specific changes in the translation of select mRNAs. New and
developing technologies are significantly advancing our ability to identify and functionally group these translationally controlled
mRNAs into gene networks based on their modes of regulation. How oncogenic AKT activates ribosome biogenesis, translation
initiation, and translational elongation to regulate these translational networks is an ongoing area of research. Currently, the majority
of therapeutics targeting translational control are focused on blocking translation initiation through inhibition of eIF4E hyperactivity.
However, it will be important to determine whether combined inhibition of ribosome biogenesis, translation initiation, and translation
elongation can demonstrate improved therapeutic efficacy in tumours driven by oncogenic AKT.
British Journal of Cancer (2011) 105, 329–336. doi:10.1038/bjc.2011.241 www.bjcancer.com
Published online 19 July 2011
& 2011 Cancer Research UK
Keywords: AKT; eIF4E; translational control; ribosome; PI3K; mTOR















































TRANSLATIONAL CONTROL BY AKT
Protein synthesis is one of the most costly and tightly regulated
energetic investments downstream of AKT signalling. AKT
regulates protein synthesis through the phosphorylation of multiple
downstream targets that function together to control all stages of
mRNA translation from ribosome biogenesis to translation initia-
tion and elongation (Figure 1). Ribosome biogenesis, translation
initiation, and translation elongation are all frequently deregulated
in cancer, and it is likely that oncogenic AKT drives tumour
development and progression in part through its ability to
coordinately activate these various steps of the translational process.
AKT activates translation initiation
One of the most rapid ways that AKT signalling enhances protein
synthesis is through the activation of translation initiation.
Translation initiation is the process by which ribosomes are
recruited to the 50 untranslated region (50 UTR) of mature mRNAs
in the first step of protein synthesis. In this process, 40S ribosomal
subunits are recruited to the 7-methyl guanosine cap (50 cap) of
mRNAs by the eIF4F translation initiation complex through
interactions with eukaryotic initiation factor 3 (eIF3; Emanuilov
et al, 1978). eIF4F is a trimeric complex that resides at the cap. It is
composed of the 50 cap mRNA-binding protein eIF4E, the RNA
helicase eIF4A, and the scaffolding molecule eIF4G (Haghighat and
Sonenberg, 1997; Rogers et al, 1999). The majority of mRNA
translation begins through eIF4F association with the cap and is
known as cap-dependent translation. Translation initiation is
considered to be the rate-limiting step of cap-dependent transla-
tion. eIF4E is considered as the key factor in controlling this step
(Duncan et al, 1987). This thought is based largely on the fact that
eIF4E activity is highly regulated at both the mRNA and protein
level. eIF4E is upregulated at the mRNA level by a number of
transcription factors including the oncogene MYC (Jones et al,
1996). At the protein level, eIF4E activity is controlled through an
activating phosphorylation at serine 209, as well as through
inhibitory interactions with the eIF4E-binding proteins (4EBPs;
Gingras et al, 1998; Topisirovic et al, 2004). This tight regulation of
eIF4E activity provides a rapid mechanism for cells to modulate
translation initiation in response to numerous stimuli, including
growth factor and oncogenic signalling.
AKT controls translation initiation largely through activation of
the kinase mammalian target of rapamycin complex 1 (mTORC1).
mTORC1 phosphorylates ribosomal protein (RP) S6 kinase 1/2
(S6K1/2) and the 4EBPs (Brown et al, 1995; von Manteuffel et al,
1997; Gingras et al, 1998). The 4EBPs are a family of small proteins
(4EBP1–3) that compete with eIF4G for binding to the dorsal
surface of eIF4E. In a hypophosphorylated state, 4EBPs prevent the
formation of the eIF4F complex on the 50 UTR of mRNAs by
binding to eIF4E and preventing eIF4G recruitment (Figure 2).
However, on growth factor stimulation, 4EBPs are phosphorylated
at multiple serine/threonine residues in a series initiated by
mTORC1 (Gingras et al, 1999, 2001). This leads to a conforma-
tional change that releases 4EBPs from eIF4E and allows eIF4G to
bind eIF4E and ultimately recruit the 40S ribosomal subunit to the
50 end of mRNAs. As a result, eIF4E regulates global protein
synthesis by controlling the rate that ribosomes are able to dock
onto the 50 cap of mRNAs.
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In addition to global increases in protein synthesis, eIF4E
hyperactivation is able to enhance the translation of select mRNAs
(Mamane et al, 2007). The 50 UTR of these mRNAs are believed to
be the regulatory factors that impart this selectivity. 50 UTRs can
vary in length and GC nucleotide content, resulting in a range of
secondary mRNA structures. These structures function as physical
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Figure 1 AKT signalling coordinately regulates translation. AKT is activated downstream of various cellular and oncogenic stimuli, such as receptor
tyrosine kinase (RTK) signalling, to promote protein synthesis. AKT may accomplish this through coordinated regulation of ribosome biogenesis, translation
initiation, and translation elongation. AKT-driven protein synthesis requires a full repertoire of mature ribosomes, and AKT has been shown to promote
ribosome biogenesis through both enhanced rRNA synthesis and enhanced ribosomal protein production. In addition, AKT promotes protein synthesis
through the activation of translation initiation factors that drive cap-dependent translation. This is one of the most rapid mechanisms by which AKT can
activate protein synthesis, and it occurs largely through mTORC1-dependent phosphorylation of the 4EBPs. Furthermore, AKT has been shown to affect the
efficiency of translation through the control of translation elongation factors. Translation can also be regulated through additional mechanisms, such as IRES-
mediated translation, and it remains to be seen what effect AKT signalling may have on these processes. Together, AKT regulates the multiple stages of
translation to drive both global changes in protein synthesis as well as selective changes in the translation of specific mRNAs.
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Figure 2 Targeting eIF4E hyperactivation in cancer. (A) Oncogenic AKT signalling promotes translation initiation predominantly through mTORC1-
dependent hyperactivation of eIF4E. In the absence of signalling, hypophosphorylated 4EBP binds to and inhibits eIF4E, blocking its ability to interact with
eIF4G. AKT signalling activates mTORC1, initiating a series of phosphorylations that release 4EBP from eIF4E. This allows for eIF4G binding to eIF4E and the
subsequent recruitment of the 40S ribosomal subunit. In addition, it has been shown that Ras/MAP kinase signalling can promote eIF4E hyperactivation
through downstream phosphorylation of eIF4E at Serine 209. (B) Current clinical status and proposed mechanistic targets of therapeutics designed to inhibit
eIF4E hyperactivation in cancer.
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barriers that limit the ability of the 40S ribosome to reach the
translation start site (Manzella and Blackshear, 1990). As such,
mRNAs with complex 50 UTRs have low basal rates of translation
and are exquisitely sensitive to eIF4E hyperactivation due to the
ability of eIF4E to recruit the eIF4A helicase. eIF4A recruitment
allows for enhanced unwinding of secondary structures in the 50
UTR, resulting in improved translation initiation efficiency. Genes
that are sensitive to eIF4E-mediated translation cover a range of
cellular functions, including cell cycle control (cyclin D1),
angiogenesis (VEGF), metabolism (ODC), and apoptosis (survivin
and Mcl-1) among others (Rousseau et al, 1996; Graff et al, 2007;
Mamane et al, 2007; Mills et al, 2008).
Despite the identification of mRNA targets that rely on the eIF4F
complex for efficient translation (see above), several unbiased
screens have also identified transcripts that lack complex 50 UTRs,
but are sensitive to eIF4E hyperactivation (Larsson et al, 2006;
Mamane et al, 2007). One such class of genes is the 50 TOP genes.
50 TOP genes (terminal oligopyrimidine or tract of oligopyrimidine
genes) are characterised by oligopyrimidine repeats in the 50 UTR
and predominantly encode for RPs, translation initiation factors,
and translation elongation factors (Levy et al, 1991; Avni et al,
1994, 1997). While it is still unknown how hyperactivated eIF4E
specifically regulates the translation of 50 TOP genes, the fact that
these genes do not possess complex 50 UTRs suggests that there are
other mechanisms of translational regulation downstream of eIF4E
that have not been described. How might these additional
regulatory mechanisms occur? One possible mechanism by which
eIF4E could regulate translation is through direct interaction with
inhibitory mRNA secondary structures outside of the 50 UTR.
eIF4E hyperactivation could promote unwinding of these struc-
tures through the recruitment of the eIF4A helicase, allowing for
mRNA translation. In support of this, it was recently shown that
eIF4E binds to a specific secondary structure outside of the 50 UTR
of Histone H4 mRNA to promote the translation of this mRNA in
an eIF4A-dependent manner (Martin et al, 2011).
To elucidate how unique mRNA secondary structures interact
with the translation initiation complex and the scanning ribosome,
it will require the development of techniques to determine
simultaneously the position of ribosomes on mRNAs and the
precise secondary structures at that particular location. There are
now rising technologies that may allow for this. In particular, the
ability to deep-sequence ribosome-protected mRNAs has enabled
us to determine the precise location of actively translating
ribosomes (Ingolia et al, 2009). Furthermore, through deep
sequencing, it is also now possible to determine the secondary
structures of mRNAs by using parallel analysis of secondary
structures (Kertesz et al, 2010). The combination of these two
technologies may provide a very accurate portrait of how mRNA
secondary structures control cap-dependent translation and allow
for the identification of translational networks of genes with
common regulatory elements within their mRNAs.
AKT promotes translation elongation
Although significant attention has been focused on the ability of
AKT to regulate translation initiation, evidence suggests that other
steps of translation, such as translation elongation, are also
regulated by AKT signalling. Translation elongation is the process
by which amino acid-charged tRNAs dock onto the ribosome/
mRNA complex and incorporate amino acids into the growing
nascent polypeptide chain. Multiple elongation factors are
necessary to carry out this process efficiently. The eukaryotic
translation elongation factor 2 (eEF2) mediates the translocation
step of elongation, where tRNAs move between the P and A site on
the ribosome as the ribosome migrates by one codon along the
mRNA. AKT can promote this elongation step through S6K1/2-
dependent inhibition of eEF2 kinase, a negative regulator of eEF2
(Wang et al, 2001). Thus, AKT activation not only affects
translation initiation but also the efficiency of actively translating
ribosomes. In addition, there is evidence that AKT activation may
more broadly impact translation elongation through the prefer-
ential translation of 50 TOP genes (see above), many of which
encode for translation elongation factors (Avni et al, 1997;
Mamane et al, 2007). While many mechanistic gaps still exist, it
will be important to understand the degree to which AKT-activated
translation elongation can enhance protein synthesis. Further-
more, it needs to be established if this ability of AKT to modulate
translation elongation can contribute to AKT-driven tumourigen-
esis. It is interesting to speculate that oncogenic AKT may promote
translation elongation not to cause increases in global protein
synthesis but to instead preferentially promote the translation of
select mRNAs.
AKT controls ribosome biogenesis
Protein synthesis depends on the generation of properly
assembled, mature ribosomes. The biogenesis of mature ribosomes
involves the synthesis and processing of rRNA, the synthesis of
RPs, and the proper assembly of all these components within the
nucleolus. AKT has been shown to modulate various aspects of
these processes predominantly through mTOR activation. For
example, mTOR can enhance the transcription of rDNA through
activation of transcription initiation factor 1A (TIF-1A), a RNA
polymerase I (Pol I) transcription factor. Through an indirect
mechanism, mTOR simultaneously promotes an activating phos-
phorylation and blocks an inhibitory phosphorylation of TIF-1A to
enhance rRNA synthesis (Mayer et al, 2004). In addition, mTOR
can promote rRNA synthesis through activation of another Pol I
transcription factor, upstream binding factor (UBF). Although the
precise mechanism behind mTOR-dependent UBF activation has
not been identified, S6K1 is thought to be required for UBF
activation (Hannan et al, 2003). While AKT has been shown to
enhance rRNA synthesis through multiple mechanisms, the ability
of AKT to regulate other ribosomal constituents is less well
defined. AKT activation may promote RP synthesis through
enhanced translation of 50 TOP genes (see above), which include
many RPs. In addition, it has been demonstrated in yeast that RP
synthesis is positively regulated by mTOR. In this setting, mTOR
promotes the transcription of RP genes by indirectly activating
transcription factors such as FHL1 (Martin et al, 2004). Despite
evidence that AKT signalling can regulate ribosomal biogenesis
through modulation of both rRNA synthesis and RP synthesis, the
connection between ribosomal biogenesis and protein synthesis
remains poorly defined. While studies have shown that normal
ribosomal biogenesis is in fact required for protein synthesis, it is
not clear if enhanced ribosomal biogenesis is able to drive
increased protein synthesis downstream of oncogenic AKT.
AKT and IRES-mediated translation
Another mechanism of initiating translation, which may be
targeted by AKT, is internal ribosome entry site (IRES)-mediated
translation. IRES elements are mRNA secondary structures
predominantly located within the 50 UTR (and to a lesser extent
in the coding sequence and intronic regions of mRNA) that can
associate with IRES trans-acting factors (ITAFs) to initiate
translation in a 50 cap and eIF4E-independent manner. Only a
subset of mRNAs contains IRES sequences. Thus, IRES-mediated
translation is thought to be a fine-tuning mechanism that controls
the translation of key mRNAs under specific physiological
conditions such as the G0/quiescent and G2/M phases of the cell
cycle, where it modulates proliferation, as well as under specific
stress conditions such as hypoxia, where it promotes cell survival
and angiogenesis (Pyronnet et al, 2000; Miskimins et al, 2001;
Kullmann et al, 2002; Braunstein et al, 2007). IRES-mediated
translation has been shown to have a role in cancer. One example
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for this is in the setting of hypoxia in invasive breast cancer,
where it has been demonstrated in a mouse model that eIF4E-
mediated translation is downregulated through increased expres-
sion of 4EBP1 under hypoxic conditions. Despite a resulting
decrease in overall protein synthesis levels, specific IRES contain-
ing mRNAs such as VEGF, HIF-1a, and Bcl-2 are translated at
higher rates, thereby increasing the protein levels of these
protumourigenic targets (Braunstein et al, 2007). In this manner,
IRES-mediated translation enhances survival under specific
cellular conditions.
Recently, there has been intriguing evidence that AKT may
regulate IRES-mediated translation at the level of ITAFs. In
particular, AKT was shown to directly phosphorylate the ITAF
hnHRP1A at serine 199 and inhibit IRES-mediated translation
(Jo et al, 2008). In this way, AKT may actively limit IRES-mediated
translation through phosphorylation of ITAFs while it simulta-
neously promotes cap-dependent translation (see above). Further
studies will be needed to delineate the role that inhibition of IRES-
mediated translation has in AKT-driven tumour development and
progression.
AKT signalling functions as a critical node for mRNA
translation, coordinating everything from ribosome biogenesis to
translation initiation and elongation. AKT collectively activates
these stages of translational control to drive increased cellular
protein synthesis. Despite strong evidence that AKT signalling can
regulate ribosome biogenesis, translation initiation, and transla-
tion elongation, we still do not understand the relative role that
these events have in AKT-induced protein synthesis. Future
studies will be needed to determine the extent to which activation
of these translational steps, either alone or in combination, is
sufficient to drive protein synthesis. In addition, it will be
important to understand the requirement for activation of each
of these translational stages in tumours driven by oncogenic AKT
signalling. Despite the fact that AKT functions as a master
regulator of translational control through mTOR activation, AKT
also has other well-characterised targets, including but not limited
to FOXO, GSK3, and MDM2, which control diverse cellular
processes, such as cell survival, proliferation, and angiogenesis,
without directly impinging on mRNA translation (Manning and
Cantley, 2007). For example, AKT-mediated phosphorylation and
activation of MDM2 leads to p53 ubiquitination, degradation, and
significantly impairs the cellular DNA damage response (Zhou
et al, 2001). Thus, oncogenic AKT exhibits its transforming
potential through multiple mechanisms. Intriguingly, several
downstream effectors of mTOR-independent AKT targets have
been shown to be translationally regulated. For example, AKT
promotes cell survival in part through inhibition of GSK3,
preventing the phosphorylation and subsequent degradation of
the prosurvival Bcl-2 family member Mcl-1 (Maurer et al, 2006),
and Mcl-1 has also been shown to be translationally upregulated
downstream of oncogenic AKT signalling (Hsieh et al, 2010).
Therefore, it remains an open and outstanding question to what
extent AKT-mediated translational control cooperates with key
non-mTOR-dependent AKT substrates to regulate critical cellular
events to promote tumourigenesis and cancer progression.
TRANSLATION INITIATION IS CRITICALLY
REQUIRED FOR ONCOGENIC AKT ACTIVITY
The AKT signalling pathway is heavily mutated in a variety of
human malignancies. In fact, mutations of AKT pathway
components and upstream regulators cover nearly the entire
spectrum of human cancers, suggesting a broad requirement for
AKT activation in tumourigenesis (Table 1). Although genetic
alterations of AKT are relatively rare in human cancers, multiple
mouse studies have demonstrated that the expression of consti-
tutively active AKT isoforms is sufficient to drive tumourigenesis
(Mende et al, 2001; Majumder et al, 2003; Tan et al, 2008).
Furthermore, AKT hyperactivity has been shown to be critically
required for tumourigenesis caused by more frequently occurring
genetic lesions upstream of AKT signalling, such as PTEN loss
(Chen et al, 2006). Despite a wealth of knowledge on genetic
mutations leading to the oncogenic activation of AKT and a
growing appreciation for the ability of AKT to coordinately
regulate mRNA translation, the extent to which deregulated AKT
Table 1 Common mutations in the PI3K–AKT–mTOR signalling pathway
Targets Genetic alteration Cancer type
PIK3CA (phosphoinositide-3-kinase,
catalytic, a-polypeptide)
Mutations Breast, endometrial, colon, upper digestive tract, gastric, pancreas, ovarian, liver,
brain, oesophageal, lung, melanoma, urinary tract, prostate, thyroid
Amplifications Lung (squamous cell), lung (adenocarcinoma), lung (small cell), lung (non-small
cell), cervical, breast, head and neck, gastric, thyroid, oesophageal, endometrial,
ovarian, glioblastoma
PIK3CB (phosphoinositide-3-kinase,
catalytic, b-polypeptide)
Amplifications Ovarian, breast
Increase in activity and expression Colon, bladder
PDPK1 (3-phosphoinositide dependent
protein kinase-1)
Amplifications and overexpression Breast
AKT (v-akt murine thymoma viral
oncogene homologue)
AKT homologue 1 mutation (E17K)
or amplifications
Breast, colon, ovarian, lung, gastric
AKT homologue 2 amplifications Ovarian, pancreas, head and neck, breast
AKT homologue 3 mutation (E17K)
or amplifications
Skin, glioblastoma
PIK3R1 (phosphoinositide-3-kinase,
regulatory subunit-1)
Mutations Glioblastoma, ovarian, colon
PTEN (phosphatase and tensin
homologue)
Loss of heterozygosity Gastric, breast, melanoma, prostate, glioblastoma
Mutations Endometrial, brain, skin, prostate, colon, ovary, breast, haematopoietic and
lymphoid tissue, stomach, liver, kidney, vulva, urinary tract, thyroid, lung
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translational control functions as an oncogenic driver remains
largely undefined. Recent studies have, however, highlighted
a critical requirement for enhanced translation initiation
downstream of oncogenic AKT signalling. Strikingly, oncogenic
AKT seems to enhance translation initiation largely through
hyperactivation of the eIF4E translation initiation factor, which is a
bona-fide oncogene.
The oncogenic potential of eIF4E has been well described both
in vitro and in vivo. Overexpression of eIF4E is sufficient to induce
transformation of fibroblasts and primary epithelial cells in
culture, and eIF4E overexpression in mice leads to increased
cancer susceptibility in a range of tissues (Lazaris-Karatzas et al,
1990; Avdulov et al, 2004; Ruggero et al, 2004). While these
findings, along with evidence of eIF4E overexpression in human
cancers (Flowers et al, 2009; Graff et al, 2009; Wang et al, 2009),
support the notion that eIF4E is oncogenic, a direct connection
between eIF4E and translational deregulation downstream of
oncogenic AKT signalling has only recently been described. Some
of the first evidence for such a connection came from a study
showing that pharmacological inhibition of oncogenic RAS and
AKT in glioblastoma cells caused a rapid and profound change in
mRNA translation that far outweighed transcriptional changes and
was associated with loss of mTORC1-dependent phosphorylation
of 4EBPs (Rajasekhar et al, 2003). This study identified transla-
tional regulation of several mRNA targets important for cancer
development, and suggested that altered translational control
downstream of eIF4E hyperactivation may be required for AKT-
driven cellular transformation.
Our group demonstrated in vivo that hyperactivation of eIF4E is
necessary for AKT-mediated tumourigenesis. Using a T-cell
lymphoma model driven by overexpression of constitutively active
AKT, we showed that enhanced protein synthesis through eIF4E
hyperactivation was required for AKT-mediated tumourigenesis.
We found that AKT overexpressing pretumour progenitor T cells
possessed a distinct survival advantage, which was abrogated when
eIF4E hyperactivity was restored to wild-type levels. Using a
candidate gene approach, we found that this survival advantage
was due in part to translational upregulation of the antiapoptotic
Mcl-1. Importantly, we were also able to pharmacologically
inhibit eIF4E hyperactivity downstream of oncogenic AKT, which
resulted in significant inhibition of tumour growth (see below;
Hsieh et al, 2010). As such, we identified the 4EBP/eIF4E axis
as a druggable target that regulates translation downstream of
oncogenic AKT.
The requirement for eIF4E hyperactivity in AKT-driven tumours
has been further substantiated by recent studies. For example, it
was found that the efficacy of an AKT inhibitor in human cancer
cell lines correlated with its ability to inhibit phosphorylation of
4EBPs and block cap-dependent translation. This study showed
that in cell lines where AKT inhibition failed to block phospho-
rylation of 4EBPs, the MAPK signalling pathway was frequently
activated. The authors further demonstrated that combined
pharmacological inhibition of AKT and MAPK signalling was able
to inhibit phosphorylation of 4EBPs and prevent the in vivo
growth of cell lines resistant to AKT inhibition alone. Importantly,
the authors were able to attribute this combinatorial drug effect
directly to the inhibition of eIF4E hyperactivity, as the over-
expression of a non-phosphorylatable form of 4EBP1 was sufficient
to block the growth of these cells in xenografts (She et al, 2010).
In addition to 4EBP-dependent control, eIF4E activity is
positively regulated through phosphorylation at serine 209 by
the MAP kinase targets MNK1/2. Whole body expression of a
knock-in mutant of eIF4E, which can no longer be phosphorylated
at this residue, was found to decrease the incidence and grade of
prostatic intraepithelial neoplasia in a mouse prostate cancer
model driven by PTEN loss (Furic et al, 2010). While this study
supports a role for eIF4E hyperactivation downstream of
oncogenic AKT signalling, it raises several questions: Do all tissues
rely on phosphorylation of serine 209 for hyperactivation of eIF4E
downstream of oncogenic AKT signalling? More broadly, what is the
tissue-specific dependence of eIF4E hyperactivation, which could be
achieved by different mechanisms, downstream of oncogenic AKT?
Indeed, there is convincing genetic evidence that oncogenic eIF4E
alone is sufficient to drive tumourigenesis in specific tissues.
Transgenic mice that ubiquitously overexpress eIF4E show that
distinct tissues, including the lungs, liver, and the lymphoid
compartment, are more prone to oncogenic transformation
(Ruggero et al, 2004). As such, we can speculate that there may
be tissue-specific requirements for the eIF4E oncogenic activity
downstream of AKT hyperactivation in tumour development.
Although many important questions remain to be addressed, the
above studies show that eIF4E hyperactivation is not only critically
required for AKT-driven tumours but it might also serve as a node
on which multiple oncogenic signalling pathways converge, thus
representing an attractive therapeutic target.
TARGETING EIF4E HYPERACTIVATION
Antisense targeting of eIF4E – eIF4E ASO
eIF4E is a bona-fide oncogene frequently hyperactivated down-
stream of oncogenic AKT signalling, and thus represents an
attractive target for rational drug design. There are currently
several approaches being pursued to therapeutically inhibit eIF4E,
but perhaps the most direct of these approaches is the use of
specific antisense oligonucleotides (ASOs) that bind to eIF4E
mRNA and mediate its destruction by RNase H. Nanomolar
concentrations of eIF4E ASOs have been shown to decrease eIF4E
protein levels in several human cancer cell lines in vitro, reducing
protein levels of known eIF4E targets and inducing apoptosis. In
tumour xenograft models, eIF4E ASOs inhibited tumour growth
without any detectable changes in body weight or liver function.
Strikingly, control mice treated with eIF4E ASOs for 3 weeks
showed no signs of toxicity, despite reductions in eIF4E protein
levels by up to 80% in the liver, implying a critical difference in the
requirement of eIF4E for normal physiological function (Graff
et al, 2007). These studies suggest that tumours may be sensitive to
eIF4E inhibition while normal tissues are not, but for what
duration and to what extent eIF4E can be inhibited system-wide
without detriment remains an open question.
eIF4E–eIF4G interaction inhibitor – 4EGI-1
Additional attempts to target eIF4E have focused on blocking its
ability to interact with eIF4G. The interaction between eIF4E and
eIF4G is dependent on an eIF4G Y(X)4LF motif, where X is
variable and F is hydrophobic (Altmann et al, 1997). High-
throughput screens for inhibitors that could prevent eIF4E binding
to the Y(X)4LF motif identified 4EGI-1 as a candidate compound.
4EGI-1 was able to inhibit eIF4F complex formation at micromolar
concentrations. Surprisingly, 4EGI-1 did not block the ability of
eIF4E to bind to 4EBP1, which, similar to eIF4G, contains a
Y(X)4LF motif. 4EGI-1 was shown to be cytostatic and cytotoxic in
multiple cell lines and preferentially blocked the growth of
transformed cells over untransformed cells (Moerke et al, 2007).
Recently, it has been reported that 4EGI-1 functions through an
eIF4G/eIF4E-independent mechanism to promote apoptosis in
human lung cancer cells (Fan et al, 2010). Additionally, 4EGI-1 has
been shown to suppress translation in primary human cells at
concentrations below those required for eIF4E inhibition (McMa-
hon et al, 2011). Collectively, these studies suggest that 4EGI-1 may
have antitumour efficacy through more general inhibition of
oncogenic pathways and that the full spectrum of protein–protein
interactions and pathways that 4EGI-1 blocks still needs to be
determined. Despite these concerns, specifically targeting the
Blocking aberrant translational control as a novel therapeutic target
AC Hsieh et al
333
British Journal of Cancer (2011) 105(3), 329 – 336& 2011 Cancer Research UK
eIF4E/eIF4G protein–protein interaction is an attractive thera-
peutic approach, and subsequent generations of such inhibitors
may provide a novel and important way of targeting eIF4E in
human cancers.
Targeting the eIF4E-50 cap interaction – Ribavirin
eIF4E function can also be directly inhibited by blocking its ability
to interact with the 50 cap of mRNAs. Ribavirin, a guanosine
ribonucleoside currently used as an anti-viral therapy, has recently
been shown to compete with endogenous mRNAs for binding to
eIF4E, leading to decreased eIF4F complex formation in vitro. In
line with this, ribavirin blocked eIF4E-mediated oncogenic
transformation in vitro and demonstrated in vivo efficacy in
preclinical models of acute myelogenous leukaemia (AML) and
squamous cell carcinoma (Kentsis et al, 2004). In a phase I dose-
escalation trial with ribavirin, 7 out of 11 AML patients were
reported to have at least partial responses or stable disease
(Assouline et al, 2009). Although ribavirin may ultimately prove to
have clinical efficacy in human cancers, the specific function of
ribavirin as a cap-mimetic has been called into question by two
independent groups (Westman et al, 2005; Yan et al, 2005).
Therefore, it is not clear if the inhibition of cap-dependent
translation underlies ribavirin’s therapeutic efficacy.
Inhibition of eIF4E phosphorylation – MNK kinase
inhibitors
The MNK kinases are activated downstream of MAP kinase
signalling and directly phosphorylate eIF4E at serine 209 (Scheper
et al, 2001). Mutation of eIF4E at this residue blocks its
transforming potential in vitro and can inhibit PTEN-driven
tumourigenesis in vivo (Furic et al, 2010). Furthermore, mice
doubly deficient for MNK1 and MNK2 are resistant to lympho-
magenesis driven by PTEN loss, validating the MNKs as potential
therapeutic targets upstream of eIF4E (Ueda et al, 2010). Recently,
a high-throughput screen identified the antifungal cercosporamide
as a potent inhibitor of MNK1 and MNK2 with limited activity
towards other kinases. Cercosporamide was able to block eIF4E
phoshorylation in vivo and inhibit the growth of human xenografts
as well as the metastasis of mouse melanoma cells (Konicek et al,
2011). Although these results are promising and suggest that
targeted inhibition of eIF4E phosphorylation may be a valid
therapeutic approach, it remains unclear to what extent the
efficacy of MNK kinase inhibitors can be attributed to their ability
to block other downstream phosphorylation targets critical for
tumour growth and maintenance. Regardless, the observation that
both MNK kinase activity and eIF4E phosphorylation are
dispensable for normal growth and development, but are required
for tumourigenesis, makes the MNK kinases attractive therapeutic
targets.
mTOR ATP active-site inhibitors
Perhaps one of the most promising approaches to therapeutically
block eIF4E hyperactivity is the targeted inhibition of the mTOR
kinase. First-generation allosteric mTOR inhibitors such as
rapamycin, RAD001, and CCI-779 inconsistently inhibit phosphor-
ylation of 4EBP1 downstream of mTORC1, despite potently
inhibiting S6K phosphorylation (Choo et al, 2008; Hsieh et al,
2010). This suggests that phosphorylation of S6K or its down-
stream target rpS6 may not serve as an accurate readout for
inhibition of all mTORC1 kinase activity. Indeed, the poor clinical
performance of rapamycin and its associated analogues in human
cancer is most likely due to their inability to block mTORC1-
dependent phosphorylation of 4EBPs and thus fully inhibit eIF4E
activation (see above). In order to overcome the incomplete
inhibition seen with allosteric mTOR inhibitors, our group and
several others have identified mTOR ATP active-site inhibitors,
such as PP242 and Torin1 (Feldman et al, 2009; Thoreen et al,
2009). These compounds reversibly compete with ATP for binding
to the mTOR catalytic domain and thus block not only mTORC1
activity, but also mTORC2 activity. mTORC2, an mTOR complex
distinct from mTORC1, is responsible for an activating phosphor-
ylation of AKT at Serine 473. Using PP242, our group was the first
to demonstrate that these ATP active-site inhibitors effectively
inhibit phosphorylation of the 4EBPs, the S6Ks, and AKT. This is
in striking contrast to rapamycin, which predominantly blocks the
phosphorylation of S6Ks and infrequently blocks the phosphor-
ylation of 4EBPs. As a result, PP242 inhibits the proliferation of
cultured cell lines to a much greater extent than rapamycin.
Furthermore, our group has shown that PP242 dramatically
inhibits tumour growth in an AKT-driven mouse model of
lymphoma that is inherently resistant to rapamycin. Strikingly,
tumours from the same model that overexpressed a mutated non-
phosphorylatable 4EBP1 transgene were completely insensitive to
PP242 inhibition, suggesting that PP242 efficacy may be entirely
due to its ability to block mTORC1-dependent 4EBP phosphoryla-
tion (Hsieh et al, 2010). In line with this, PP242 and Torin1 both
retain their antiproliferative effects in mouse embryonic
fibroblasts, in which the mTORC2 complex has been destabilised
(Feldman et al, 2009; Thoreen et al, 2009). Although these studies
suggest that the antitumour effect of mTOR ATP active-site
inhibitors is predominantly mediated by blocking phosphorylation
of 4EBPs and eIF4E hyperactivity, they cannot generally rule out a
role for the inhibition of other translational regulators downstream
of mTORC1. Furthermore, it remains to be seen how these ATP
active-site inhibitors, which have been found to block growth of
cell lines and murine lymphomas, will perform in solid human
epithelial tumours.
FUTURE DIRECTIONS
Oncogenic AKT signalling utilises the multistep process of mRNA
translation to drive tumour development and progression. Despite
significant advances in our understanding of AKT-mediated
translational control and the development of promising therapeu-
tics to target deregulated translation initiation in human cancers,
many questions and opportunities remain. Although AKT signal-
ling has been shown to control the translational steps of ribosome
biogenesis, translation initiation, and translation elongation, it is
still an open question if oncogenic AKT requires the hyperactiva-
tion of all three translational steps for tumourigenesis and cancer
progression. This is an important question because most
preclinical and clinical studies to date have focused on targeting
translation initiation downstream of oncogenic AKT. Recently, it
has been shown that targeting ribosome biogenesis through pol I
inhibition (CX-5461) or targeting various aspects of translation
elongation leads to significant antitumour activity in vivo (Robert
et al, 2009; Drygin et al, 2011). Thus, it will be important to
determine whether more comprehensive inhibition of oncogenic
AKT-driven translation through combined targeting of ribosome
biogenesis, translation initiation, and translation elongation results
in clinically significant improvements in patient survival. Attempts
to target translational control downstream of oncogenic AKT will
be further aided by the use of novel technologies and analyses to
identify networks of translationally controlled genes that may
function as critical biomarkers for disease progression and
therapeutic response.
Finally, there is a growing body of evidence that deregulation of
translational control may be a common mechanism by which
oncogenic pathways promote tumour initiation and progression
(e.g., MYC and RAS). As such, efforts to target translational
control may prove successful in a wide array of human
malignancies.
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